
Physician-reviewed low-T & fertility education
LH and FSH help identify why testosterone is low. hCG and enclomiphene can be considered in selected men—especially when preserving testicular function or fertility matters—but they are not interchangeable with TRT and are not appropriate for every cause of hypogonadism.
Medically reviewed by Dr. Timothy Mackey
Medical Director · Updated September 2026

★★★★★4.9 Google rating
A+ · BBBAccredited rating
FERTILITY-AWAREIndividualized hormone planning
LH and FSH are diagnostic clues, not just numbers to “optimize.” Low testosterone with elevated LH can suggest primary testicular dysfunction, while low testosterone with low or inappropriately normal LH may suggest secondary hypogonadism. FSH is particularly useful when fertility and sperm production are concerns.
hCG can stimulate the LH receptor in the testes. Enclomiphene can increase endogenous LH and FSH by blocking estrogen feedback at the hypothalamic-pituitary level. Whether either approach is appropriate depends on the cause of low T, fertility goals, testicular function and the patient's overall medical picture.
The hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates Leydig cells in the testes to produce testosterone. FSH acts primarily on Sertoli cells and is important for spermatogenesis.
Testosterone and estradiol then provide feedback to the hypothalamus and pituitary. This hypothalamic-pituitary-gonadal, or HPG, axis helps maintain reproductive and androgen function.
LH can help distinguish primary from secondary hypogonadism. If testosterone is low and LH is elevated, the pituitary is signaling the testes strongly but the testes may not be responding adequately. If testosterone is low and LH is low or unexpectedly normal, the signaling problem may be hypothalamic or pituitary—or related to obesity, medications, systemic illness, sleep disorders or other potentially reversible factors.
No single LH value should be interpreted without the testosterone result, symptoms and laboratory reference range.
FSH is especially relevant to sperm production. An elevated FSH can indicate impaired seminiferous-tubule or Sertoli-cell function, while a low or inappropriately normal FSH may occur with hypothalamic or pituitary suppression.
For a man concerned about fertility, semen analysis often provides more direct information than FSH alone. Hormone testing and semen testing answer different questions.
PatternTypical clueTreatment implicationsPrimary hypogonadismLow testosterone with elevated LH/FSHTestes may respond poorly to stimulation; TRT may be more effective for androgen replacement when appropriate.Secondary hypogonadismLow testosterone with low or inappropriately normal LH/FSHCause should be investigated; selected men may respond to therapies that stimulate endogenous signaling.
Human chorionic gonadotropin (hCG) binds to the same LH receptor used by luteinizing hormone. In men with responsive testes, hCG can stimulate intratesticular testosterone production.
hCG has FDA-approved labeling for selected cases of hypogonadotropic hypogonadism in males, depending on the specific product. In clinical practice it may also be used in fertility-focused regimens and in selected men receiving testosterone, but the exact use, dose and goal should be individualized.
Exogenous testosterone suppresses pituitary LH and FSH and can markedly reduce intratesticular testosterone and sperm production. hCG can maintain testicular stimulation in some men, but it should not be presented as a guarantee that fertility will be preserved while on TRT.
The 2024 AUA/ASRM guideline advises against prescribing exogenous testosterone to men interested in current or future fertility. Adding hCG or a SERM does not remove that concern; evidence for preserving fertility with such combinations is too limited to recommend this approach. Depending on semen parameters and diagnosis, gonadotropin treatment may involve hCG and, in some cases, FSH activity under specialist supervision. See our TRT and fertility guide.
Yes, in selected men with adequate testicular function and an appropriate diagnosis, hCG may be used to stimulate endogenous testosterone rather than replace it directly. Response varies, and it is generally less useful when the testes themselves have significant primary failure.
Follow-up testosterone, estradiol, symptoms and fertility measures may be relevant depending on the treatment goal.
Enclomiphene is the trans-isomer of clomiphene and acts as a selective estrogen receptor modulator. By reducing estrogen feedback at the hypothalamus and pituitary, it can increase endogenous GnRH signaling and raise LH and FSH, which can then increase testicular testosterone production in men whose HPG axis and testes remain responsive.
Enclomiphene is not FDA-approved in the United States for treatment of male hypogonadism. Enclomiphene is not an FDA-approved standalone drug. Compounded enclomiphene is an unapproved preparation; this differs from off-label prescribing of an approved medication such as clomiphene.
Clomiphene is a mixture of enclomiphene and zuclomiphene isomers. Enclomiphene contains the trans-isomer alone. Research has examined enclomiphene as a way to raise testosterone while maintaining gonadotropin signaling, but this does not establish it as universally safer or superior to clomiphene.
Read our comparison of enclomiphene vs. clomiphene.
Selected men with secondary hypogonadism, functioning testes and a desire to preserve fertility may be reasonable candidates for therapies that stimulate endogenous testosterone production. Potential causes of secondary hypogonadism—such as obesity, sleep apnea, opioid use, hyperprolactinemia, pituitary disease or systemic illness—should also be considered rather than skipped.
Men with primary testicular failure are less likely to respond because the signaling pathway may be intact while the testes themselves cannot respond adequately.
TRT may be the more appropriate treatment when true testosterone deficiency is confirmed and endogenous stimulation is unlikely to provide adequate androgen replacement, is contraindicated, is ineffective, or does not fit the patient's goals.
TRT provides exogenous testosterone but suppresses LH and FSH while it is being used, which makes fertility counseling important before treatment. See the NovaGenix TRT guide.
See our detailed guide to blood testing before TRT.
hCG can increase testosterone and estradiol and may cause breast tenderness, fluid retention, acne or other hormone-related effects. Enclomiphene and other SERMs can also cause adverse effects and should not be assumed to be risk-free because they stimulate endogenous production.
For more on product-specific uncertainties, see enclomiphene evidence and safety. Monitoring should follow the treatment goal: testosterone response, symptoms, estradiol when clinically relevant, CBC/hematocrit where appropriate, fertility measures when needed, and evaluation of new adverse effects.
Sometimes endogenous testosterone recovers after removal of a reversible suppressive factor or after discontinuation of exogenous testosterone, but no medication can guarantee a permanent reset of the HPG axis. Recovery depends on the cause of suppression, duration of treatment, age, baseline testicular function and other factors.
Claims that a short course will reliably “restart” every man's testosterone production should be viewed skeptically.
Exogenous testosterone usually suppresses GnRH, LH and FSH through negative feedback. This is why sperm production and testicular volume can decrease during TRT.
No, but hCG binds to the LH receptor and can mimic much of LH's action at the testes.
Not reliably in every man. It may help maintain intratesticular testosterone and spermatogenesis in selected patients, but men actively pursuing fertility need individualized evaluation and often semen monitoring.
No. Enclomiphene is not FDA-approved in the United States for male hypogonadism.
It is generally less compelling when LH is already elevated because the pituitary is already signaling strongly and the limiting problem may be testicular responsiveness.
NovaGenix can review testosterone, LH, FSH, fertility goals, medical history and prior therapy before discussing whether TRT, hCG, enclomiphene or another approach is appropriate. Learn about Dr. Timothy Mackey and NovaGenix Health & Wellness.
Call 561-277-8260 | Text NovaGenix | Schedule a Consultation
Related: hCG Therapy in Jupiter, FL
This article is educational and does not replace individualized diagnosis, fertility evaluation or prescription guidance.
Compare the treatment mechanisms in our hCG vs. Clomid guide.
Speak with NovaGenix about physician-led evaluation, testing, and treatment options in Jupiter, Florida.
Medical disclaimer: This article is for general educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Reading it does not create a physician-patient relationship. Always consult a qualified healthcare professional about your individual circumstances, and never delay seeking care because of something you read here. If you are experiencing a medical emergency, call 911. Read our full Medical Disclaimer.


609 N Hepburn avenue suite 106. Jupiter, Florida 33458
609 N Hepburn avenue suite 106. Jupiter, Florida 33458
561-277-8260
Learn what you want to know about hormone therapy by scheduling a free consultation.
Contact Us Today609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Monday - Friday: 9:00 am - 5:00 pm | Saturday-Sunday: Closed